Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 6
Submit an article Journal homepage
944
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What can be done pharmacologically for a subject with severe refractory constipation-predominant irritable bowel syndrome?

Gabrio Bassottia Gastroenterology & Hepatology Section, Department of Medicine, University of Perugia Medical School, Perugia, Italy;b Gastroenterology Unit, Santa Maria della Misericordia Hospital, Perugia, ItalyCorrespondence[email protected]
View further author information
Pages 617-618 | Received 31 Aug 2019, Accepted 16 Jan 2020, Published online: 28 Jan 2020

References

  • Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017;376:2566–2578.
  • Munjal A, Dedania B, Cash B. Update on pharmacotherapy for irritable bowel syndrome. Curr Gastroenterol Rep. 2019;21:25.
  • Lacy BE. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:817–830.
  • Lacy BE, Everhart KK, Weiser KT, et al. IBS patients’ willingness to take risks with medications. Am J Gastroenterol. 2012;107:804–809.
  • Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2011;26(Suppl 3):116–118.
  • Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment evaluation: the “CHRO.CO.DI.T.E.” study. BMC Gastroenterol. 2017;17:11.
  • Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1–18.
  • Soncini M, Stasi C, Usai Satta P, et al. IBS clinical management in Italy: the AIGO survey. Dig Liver Dis. 2019;51:782–789.
  • Markham A. Tenapanor: first approval. Drugs. 2019;79:1897–1903.
  • Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155:1753–1763.
  • Morrow T. $850 per bowel movement? Hard to justify that cost. Manag Care. 2017;26:36–37.
  • Bassotti G, Usai-Satta P, Bellini M. Linaclotide for the treatment of chronic constipation. Expert Opin Pharmacother. 2018;19:1261–1266.
  • Chedid V, Vijayvargiya P, Camilleri M. Elobixibat for the treatment of constipation. Expert Rev Gastroenterol Hepatol. 2018;12:951–960.
  • Bassotti G, Chistolini F, Nezpa FS, et al. Pharmacological treatment of irritable bowel syndrome: a critical assessment. Scand J Gastroenterol. 2003;38:1013–1015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.